American Journal of Ophthalmology
Volume 130, Issue 3 , Pages 287-291 , September 2000

Anterior uveitis as a side effect of topical brimonidine

  • Daniel B Byles (FRCOphth)

      Affiliations

    • Oxford Eye Hospital, Oxford, England, UK
    • ,
  • Peggy Frith (FRCP)

      Affiliations

    • Oxford Eye Hospital, Oxford, England, UK
    • ,
  • John F Salmon, MD

      Affiliations

    • Oxford Eye Hospital, Oxford, England, UK
    • Corresponding Author InformationCorrespondence to John F. Salmon, MD, Oxford Eye Hospital, Radcliffe Infirmary, Woodstock Rd, Oxford OX2 6HE, England; fax: 01865-224013

,Accepted 1 March 2000.

References 

  1. Greenfield DS, Liebmann JM, Ritch R. Brimonidine (a new alpha2-adrenoreceptor agonist for glaucoma treatment). J Glaucoma. 1997;6:250–258
  2. Schuman JS, Horwitz B, Choplin NT, et al.  A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847–852
  3. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily (1-year results in glaucoma patients. Brimonidine Study Group). Am J Ophthalmol. 1999;127:20–26
  4. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998;105:1960–1967
  5. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0. 5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41(suppl 1):S27–S37
  6. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(suppl 1):S39–S47
  7. Burke J, Manlapaz C, Kharlamb A, et al.  Therapeutic use of α2-adrenoceptor agonists in glaucoma. In:  Lanier S,  Limbird L editor. Alpha2-adrenergic receptors (structure, function and therapeutic implications). Reading: Harwood Academic; 1996;p. 179–187
  8. Butler P, Mannschreck M, Lin S, et al.  Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113:293–296
  9. Thompson CD, Macdonald TL, Garst ME, et al.  Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Exp Eye Res. 1997;64:767–773
  10. Naranjo CA, Busto U, Sellers EM, et al.  A method for estimating the probability of adverse drug reactions. Clin Pharm Ther. 1981;30:239–245
  11. Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol. 1998;42:557–570
  12. Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519–523
  13. Akingbehin T, Villada JR, Walley T. Metipranolol-induced adverse reactions (I. The rechallenge study). Eye. 1992;6:277–279
  14. Krupin T, Leblanc RP, Becker B, et al.  Uveitis in association with topically administered corticosteroid. Am J Ophthalmol. 1970;70:883–885
  15. Fraunfelder FT. In: Drug induced ocular side effects and drug interactions. Philadelphia: Lea and Febiger; 1989;p. 617–618
  16. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–268
  17. O’Connor GR. Granulomatous uveitis and metipranolol. Br J Ophthalmol. 1993;77:536–537
  18. Kamalarajah S, Johnston PB. Bilateral anterior uveitis associated with 0.3% Minims metipranolol. Eye. 1999;13:380–381
  19. Martins JC, Wilensky JT, Asseff CF, et al.  Corticosteroid-induced uveitis. Am J Ophthalmol. 1974;77:433–437

PII: S0002-9394(00)00491-8

American Journal of Ophthalmology
Volume 130, Issue 3 , Pages 287-291 , September 2000

Article Tools

* Image Usage & Resolution